Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
03/14/2023 - 08:00 AM
PVTX-321 and PVTX-405 Achieve Development Candidate Nomination
NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Proteovant Therapeutics , a Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases, today announced it will present data on PVTX-321, an estrogen receptor degrader, at the Protein Degradation & Targeting Undruggables Congress USA, March 15-16 in Boston and on PVTX-405, an IKZF2 molecular glue, at the Targeted Protein Degradation Europe Conference, March 28-30 in London.
Targeted protein degradation harnesses the body’s natural protein disposal system and offers the potential to develop new medicines targeting historically difficult-to-drug proteins that play an important role in causing serious diseases. Proteovant Therapeutics is discovering and developing best-in-class and first-in-class degraders that can engage previously undruggable targets.
“We are advancing a robust pipeline of heterobifunctional degraders and molecular glues that span a range of novel molecular targets, which are implicated in disorders where new medicines are needed,” said Drew Fromkin, CEO, Proteovant Therapeutics. “PVTX-321, our degrader targeting the estrogen receptor, is highly potent and demonstrates impressive, dose dependent tumor growth inhibition and shrinkage in preclinical models. In addition, PVTX-405 has best-in-class potential with robust IKZF2 degradation in vivo. We are enthusiastic about the progress being made across our degrader pipeline and molecular glue platform initiatives.”
Presentation at Protein Degradation & Targeting Undruggables Congress USA
Title: Discovery and Characterization of an Estrogen Receptor Heterobifunctional Degrader with Best In-Class Potential Session Time: 12:00-12:25 p.m. EDT on March 15, 2023 Presenter: Courtney Havens, Director, Biology, Proteovant Therapeutics Presentation at Targeted Protein Degradation Europe Conference
Title: Discovery and Characterization of an IKZF2 Selective Molecular Glue Degrader with Best In-Class Potential Session Time: 4:30 p.m. BST on March 29, 2023 Presenter: Harshil Dhruv, Associate Director, Biology, Proteovant Therapeutics Following the presentations at each event, materials will be made available online here .
About Proteovant Therapeutics www.proteovant.com and follow us on LinkedIn .Media Contact Liz.Boten@canalecomm.com
ROIV Rankings
#290 Ranked by Stock Gains
ROIV Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Country
UK
City
London
About ROIV
roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak
